Analysts Offer Predictions for Genelux Q1 Earnings

Posted by Brenda Bartman on Aug 19th, 2026

Genelux Corporation (NASDAQ:GNLX – Free Report) – Research analysts at Brookline Capital Markets issued their Q1 2027 earnings estimates for shares of Genelux in a research report issued on Monday, August 17th. Brookline Capital Markets analyst K. Dolliver anticipates that the company will post earnings of ($0.10) per share for the quarter. The consensus estimate for Genelux’s current full-year earnings is ($0.80) per share. Brookline Capital Markets also issued estimates for Genelux’s Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.16) EPS and Q4 2027 earnings at ($0.19) EPS.

Several other analysts also recently issued reports on GNLX. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a report on Friday, July 17th. Benchmark restated a “speculative buy” rating on shares of Genelux in a research report on Tuesday. Finally, Wall Street Zen lowered Genelux from a “sell” rating to a “strong sell” rating in a report on Saturday. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Get Our Latest Stock Analysis on Genelux

Genelux Stock Performance

Genelux stock opened at $2.60 on Wednesday. Genelux has a 1 year low of $2.29 and a 1 year high of $8.53. The firm’s 50-day moving average is $2.88 and its 200-day moving average is $2.77. The company has a market cap of $116.58 million, a P/E ratio of -3.02 and a beta of 0.60.

Genelux (NASDAQ:GNLX – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01).

Hedge Funds Weigh In On Genelux

Several institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in shares of Genelux during the 2nd quarter valued at $1,323,000. Bank of America Corp DE acquired a new position in shares of Genelux during the 2nd quarter worth $990,000. Flputnam Investment Management Co. bought a new stake in Genelux in the second quarter worth $697,000. Global Retirement Partners LLC acquired a new stake in shares of Genelux in the second quarter worth about $686,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Genelux by 451.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 183,807 shares of the company’s stock valued at $801,000 after acquiring an additional 150,463 shares in the last quarter. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Insider Activity at Genelux

In related news, Director John W. Smither sold 12,000 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $2.91, for a total value of $34,920.00. Following the completion of the transaction, the director owned 91,403 shares in the company, valued at $265,982.73. This trade represents a 11.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director John Thomas sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $2.98, for a total transaction of $29,800.00. Following the completion of the transaction, the director owned 472,784 shares of the company’s stock, valued at approximately $1,408,896.32. The trade was a 2.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,868 shares of company stock worth $76,120 in the last ninety days. Corporate insiders own 7.50% of the company’s stock.

Genelux News Roundup

Here are the key news stories impacting Genelux this week:

Positive Sentiment: HC Wainwright modestly improved its Q4 2026 EPS forecast to a loss of $0.19 from $0.20, suggesting slightly better near-term expectations. The firm continues to project positive earnings beginning in FY2028, with estimates of $0.61 per share in FY2028, $1.63 in FY2029 and $2.52 in FY2030. HC Wainwright Genelux earnings estimates
Neutral Sentiment: Brookline Capital Markets issued quarterly 2027 forecasts ranging from a $0.10-per-share loss in Q1 to a $0.19-per-share loss in Q4. The estimates indicate that Genelux is still expected to remain unprofitable throughout 2027, although the figures provide a new analyst framework for future performance. Brookline Capital Markets Genelux earnings estimates
Negative Sentiment: HC Wainwright reduced its Q3 2026 EPS estimate to a $0.21 loss from $0.20 and lowered its FY2027 forecast to a $0.77 loss from $0.75. The firm also cut its longer-term estimates for FY2028, FY2029 and FY2030, including reducing FY2030 EPS to $2.52 from $2.61. These revisions suggest weaker expected earnings and may pressure GNLX stock. HC Wainwright lowers Genelux earnings estimates
Negative Sentiment: Genelux recently reported a quarterly loss of $0.21 per share, slightly worse than the $0.20 analyst consensus. Continued losses, combined with the company’s negative price-to-earnings ratio and lack of near-term profitability, remain headwinds for investors.

About Genelux

(Get Free Report)

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.